Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer-Reference-Cited by-同舟云学术

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer

Published:2017-01 Issue:1 Volume:18 Page:60-67
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Li Tianhong,Piperdi Bilal,Walsh William V.,Kim Mimi,Beckett Laurel A.,Gucalp Rasim,Haigentz Missak,Bathini Venu G.,Wen Huiyu,Zhou Kaili,Pasquinelli Patricia B.,Gajavelli Srikanth^ORCID,Sreedhara Meera,Xie Xianhong,Lara Primo N.,Gandara David R.,Perez-Soler Roman

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference62 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Cancer treatment and survivorship statistics, 2016;Miller;CA Cancer J Clin,2016

3. Genotyping and genomic profiling of non–small-cell lung cancer: implications for current and future therapies;Li;J Clin Oncol,2013

4. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

5. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain;BMC Pulmonary Medicine;2023-02-21

2. A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer;Journal of Comparative Effectiveness Research;2023-02

3. Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain;BMC Cancer;2022-03-19

4. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario;BMC Cancer;2021-06-10

5. Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response;Chinese Medical Journal;2020-09-21